Pick · 5.0% · large · Health Care · last 109.72
Entry 104.00–108.00 · Stop 99.00 · Target 123.00 · Buy ≈ 24 shares (≈ $2,633 at 109.72)
Thesis (long, position, conviction 68)
Thesis carried over from the 2026-10-01 run.
Bull: Halozyme is compounding top-line growth at an exceptional rate (Q2 2026 revenue +47.7% YoY to $481.0M, F-HALO-4) while operating leverage keeps expanding — operating income of $287.7M implies a ~60% operating margin and net income of $229.9M implies a ~48% net margin (F-HALO-5, F-HALO-6). Diluted EPS of $1.90 in the quarter (F-HALO-7) annualizes to roughly $7.5-8/share, putting the stock on a forward P/E in the mid-teens for a business growing revenue near 50% YoY — an unusually cheap multiple for the growth and margin profile. FY2025 operating cash flow of $651.6M (F-HALO-8) confirms the earnings are cash-backed, not accounting artifacts. The Street agrees: 13 of 16 covering analysts rate it buy/strong-buy with zero sells (F-HALO-12), and the Q2 print beat consensus EPS by 21.7% (F-HALO-11). The stock has already demonstrated strong momentum (+34.6% over 3 months, +31.8% relative to the S&P, F-HALO-2) yet sits 7.2% below its 52-week high and below its 20-day MA while holding comfortably above its rising 50-day MA (F-HALO-1, F-HALO-3), giving a reasonable technical entry after a modest pullback rather than chasing a spike. The September convertible notes raise ($1.5B, 1.5% coupon, F-HALO-9) was done with capped calls to manage dilution and proceeds partly used to retire older converts (F-HALO-10) — a balance-sheet optimization, not a sign of cash need, and the ~$139.84 conversion price is ~31% above the current share price, so near-term dilution risk is low. A new board addition (F-HALO-13) is a minor positive governance signal.
Bear: The $1.5B convertible issuance (F-HALO-9, F-HALO-10) still represents real potential share-count dilution if the stock appreciates toward $139.84, and adds financial complexity; the brief flags conflicting debt-to-equity figures between data vendors (1517.7 vs 14.95) that are unreconciled, making leverage hard to assess cleanly. The stock has already rallied 34.6% in three months (F-HALO-2), so much of the growth/margin story may be priced in, and it is currently trading below its 20-day MA, suggesting near-term momentum has cooled (F-HALO-1). The EPS figures from different sources ($1.90 diluted vs. $2.28 reported surprise basis) are not reconciled, creating some uncertainty about the "clean" earnings run-rate used for valuation. Halozyme's revenue is heavily dependent on partner royalty/collaboration economics (ENHANZE platform), a concentration risk not detailed in this brief, and any single-customer or litigation shock isn't captured in the data provided.
Valuation: Using Q2 2026 diluted EPS of $1.90 (F-HALO-7) annualized (~$7.5-8/share run-rate) against the $106.94 close (F-HALO-1), HALO trades near 14x trailing-ish earnings while still growing revenue ~48% YoY (F-HALO-4) and operating margins near 60% (F-HALO-5) — a low multiple relative to the growth/margin combination if the growth rate persists even partially. FY2025 operating cash flow of $651.6M against a sub-$15B-implied market cap range also supports a reasonable FCF yield, though the brief does not supply market cap or a precise FCF yield figure, so this view is directional rather than precise. The analyst consensus skew to buy/strong-buy (F-HALO-12) is consistent with a re-rating case rather than a stretched valuation.
Catalysts
2026-11-02: Q3 2026 earnings report (consensus EPS ~$2.397, revenue ~$499.4M) — a beat/raise would confirm the growth trajectory and likely push shares toward/through the 52-week high
F-HALO-1: HALO closed at $106.94 on 2026-10-01, below its 20-day moving average of $110.28 and above its 50-day moving average of $102.35. (as of 2026-10-01)[E2891]
F-HALO-2: The stock returned 34.6% over the three months through 2026-10-01; its three-month relative strength versus the S&P 500 was 31.77%. (as of 2026-10-01)[E2891]
F-HALO-3: HALO's 2026-10-01 close was 7.19% below its 52-week high closing price of $115.22. (as of 2026-10-01)[E2891]
F-HALO-4: Revenue for the quarter ended 2026-06-30 was $481.0 million, up 47.7% from $325.7 million in the quarter ended 2025-06-30. (as of 2026-06-30)[E2892]
F-HALO-5: Operating income for the quarter ended 2026-06-30 was $287.7 million, up 42.1% from $202.4 million in the quarter ended 2025-06-30. (as of 2026-06-30)[E2892]
F-HALO-6: Net income for the quarter ended 2026-06-30 was $229.9 million, up 39.2% from $165.2 million in the quarter ended 2025-06-30. (as of 2026-06-30)[E2892]
F-HALO-7: Diluted EPS for the quarter ended 2026-06-30 was $1.90, compared with $1.33 for the quarter ended 2025-06-30. (as of 2026-06-30)[E2892]
F-HALO-8: Annual revenue was $1.397 billion in calendar 2025, compared with $1.015 billion in 2024; operating cash flow in 2025 was $651.6 million. (as of 2025-12-31)[E3624]
F-HALO-9: Halozyme completed a $1.5 billion offering of 1.50% convertible senior notes due 2033 on 2026-09-22; the initial conversion price was approximately $139.84 per share. (as of 2026-09-22)[E3620, E3629]source
F-HALO-10: The company said it received approximately $1.471 billion in net proceeds from the notes offering and planned to use proceeds for capped-call transactions and repurchases of existing convertible notes, among other uses. (as of 2026-09-22)[E3620, E3629]source
F-HALO-11: For the quarter ended 2026-06-30, the earnings-calendar source reported EPS of $2.28 against its estimate of $1.8727, a 21.7% positive surprise. (as of 2026-06-30)[E3623]
F-HALO-12: Analyst recommendations reported for September 2026 comprised 3 strong-buy, 10 buy, 3 hold, and no sell or strong-sell ratings. (as of 2026-09-01)[E2914]
F-HALO-13: Halozyme reported that James Daly was elected to its board on 2026-09-28, with a term ending at the 2029 annual meeting. (as of 2026-09-28)[E3625]source
Critic
O3 (major): The smaller position and lower entry improve the trade, but the valuation rationale remains unreconciled. Open: Valuation defended on EPS basis, but leverage and convertible-note risk remain unresolved; position cut to 5% with a lower entry zone.
What would change the view
A close below $99 (stop level) invalidating the technical setup
Q3 2026 revenue growth decelerating sharply below ~30% YoY, signaling the 47.7% growth rate (F-HALO-4) was not durable
Clear evidence that the convertible notes were raised to fund an operating cash shortfall rather than refinance existing converts
Confirmation that reported leverage is near the higher vendor figure (debt/equity ~15x) rather than the lower one, indicating balance-sheet stress
Data quality
Quality score 100/100.
Gap: The quote block is timestamped 2026-10-02, after the pack's stated date of 2026-10-01; the analysis uses the daily close dated 2026-10-01 instead.
Gap: Reported debt-to-equity figures conflict substantially between data vendors: Yahoo reports 1517.7 while Finnhub reports 14.95; the figures are not reconciled in the supplied data (E2892).
Gap: The earnings-calendar EPS surprise figure differs from the SEC-derived diluted EPS for Q2 2026; the supplied data does not explain the difference in EPS definitions (E2892, E3623).
Red flag: The $1.5 billion convertible-note issuance creates potential dilution if notes convert; the initial conversion price is approximately $139.84 per share (E3620, E3629).